A look at the latest research from multiple corners of ophthalmology, from gene therapy to dry eye.
Alcaftadine was significantly more effective than olopatadine in reducing the itching caused by grass pollen at 16 hours after dosing
Putting two drugs together in one formulation can sometimes achieve better results than either agent can by itself.
Numerous approaches to treatment of dry AMD are under development.
Ophthalmic Product Development Insights
A discussion of gland mechanisms, how they can go awry and what you can do to nurse them back to health.
Explaining both the demands and potential rewards of a clinical trial can make patients more likely to participate fully in the protocol.
Dr. Hollander joins Ora after 10 years as industry leader at Allergan. Meet Ora’s New Chief Medical Officer at ARVO